Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: biosimilars

ACR to Lead Resolutions at June AMA House of Delegates Meeting

  |  

The ACR will co-lead with the American Society of Clinical Oncology a resolution on in-office dispensing of specialty drugs and will lead 10 other specialty societies to advance a resolution on the proposed NIH Public Access Plan and equitable access to quality clinical research.

Psoriatic Arthritis Drugs at a Glance, 2023

Mary Choy, PharmD, BCGP, FASHP  |  

Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

The ACR Takes a Stand: How Position Statements Are Created

Catherine Kolonko  |  

Through the development of position statements that lay out the ACR’s official stance on issues related to the management of rheumatic and musculoskeletal conditions, the Committee on Rheumatologic Care helps outline policies that affect the practice of rheumatology and the wellbeing and care of patients.

First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles

  |  

After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.

FDA Officials Speak Out: New Approvals & Safety Concerns Discussed

  |  

PHILADELPHIA—Officials from the U.S. Food & Drug Administration discussed recent drug approvals and drug safety issues at ACR Convergence in November in a session that captured the flurry of activity in the rheumatology sphere at the agency over the past year. Sabiha Khan, MD, clinical reviewer in the Division of Rheumatology and Transplant Medicine at…

Cliff Diving: Evergreening & Other Oddities

  |  

The glassblowers were in revolt. The island of Murano, in the 13th century, was a perfect home for the glassblowing industry. Connected to Venice through a system of bridges, Murano was surrounded by waters that protected the city from the furnaces that fueled the glassblowers’ craft. The Republic of Venice dominated trade throughout the Mediterranean,…

FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA

  |  

Based on findings from a double-blind, placebo-controlled study evaluating its efficacy and safety, rituximab-arrx has received FDA approval for the treatment of patients with rheumatoid arthritis.